Administering RSV Prefusion F Protein Vaccine With The Adjuvanted Seasonal Quadrivalent Influenza Vaccine Stimulated Adequate Immune Response, Was Safe In Older Adults, Trial Shows

MedPage Today (8/7, Kahn) reports, “Administering the respiratory syncytial virus (RSV) prefusion F protein vaccine (Arexvy) at the same time as the adjuvanted seasonal quadrivalent influenza vaccine stimulated an adequate immune response and was safe in older adults, a phase III randomized trial showed.” Researchers observed that “among adults ages 65 and older, co-administration of the RSV and influenza vaccines resulted in hemagglutination inhibition titers that were noninferior to those with sequential administration for three out of four influenza strains, as well as noninferior neutralization titers for the RSV-A and RSV-B subtypes, at 1 month after vaccination.” The findings were published in Clinical Infectious Diseases.